Cantor Fitzgerald Reiterates Overweight on Longboard Pharmaceuticals, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Longboard Pharmaceuticals (NASDAQ:LBPH) and maintained a $60 price target.
June 20, 2024 | 1:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Longboard Pharmaceuticals and maintained a $60 price target, indicating strong confidence in the company's future performance.
The reiteration of an Overweight rating and a maintained price target of $60 by a reputable analyst suggests strong confidence in Longboard Pharmaceuticals' future performance. This is likely to positively impact the stock price in the short term as investors may view this as a bullish signal.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100